HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Kim, Y. M. Articles by Lim, S.-K. Search for Related Content PubMed PubMed Citation Articles by Kim, Y. M. Articles by Lim, S.-K.

Division of Endocrinology, Department of Internal Medicine, NHIC Ilsan Hospital, Goyang, Republic of Korea
¹ Division of Endocrinology, Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, South Korea
² BK21 Project for Medical Science, College of Medicine, Yonsei University, Seoul, South Korea
³ College of Medicine, Institute of Endocrine Research, Yonsei University, Seoul, South Korea
⁴ Division of Endocrinology, Department of Internal Medicine, YanBian University, Medical College, Affiliated Hospital, YanJi, People’s Republic of China

(Requests for offprints should be addressed to S-K Lim who is now at Division of Endocrinology, Department of Internal Medicine, College of Medicine, Yonsei University, 134 Shinchon-dong Seodaemun-ku, PO Box 120-749, Seoul, South Korea; Email: lsk{at}yumc.yonsei.ac.kr)

The systemic treatment with angiogenesis inhibitor has been shown to result in weight reduction and adipose tissue loss in various models of obesity. To verify the mechanism of CKD-732 (TNP-470 analog) against obesity, we evaluated CKD-732’s peripheral and central anti-obesity effects. CKD-732 was injected subcutaneously (s.c.) for 7 days in various animal models and intracerebroventricularly (i.c.v.) in arcuate nucleus (ARC) lesion mice, ob/ob mice, and normal littermates. Modulation of the hypothalamic neuropeptide mRNAs after i.c.v. injection was evaluated in ARC lesion mice and normal littermates. A conditioned taste aversion (CTA) was performed using lithium chloride (LiCl) as a positive control agent in Long–Evans Tokushima Otsuka and Otsuka Long–Evans Tokushima fatty (OLETF) rats. As a result, 7 days of CKD-732 s.c. injection reduced the cumulative food intake and the body weight significantly in both treated obese (e.g. 114.8 ± 13.4 g vs 170.7 ± 20.6 g, 7.9 ± 0.5% decrease vs 0.3 ± 2.2% decrease; in treated OLETF rat versus control OLETF rat, P < 0.01 respectively) and non-obese models. Epididymal and mesenteric fat pads, and the size of adipocytes were significantly decreased in treated rats. A single i.c.v. injection decreased food intake and body weight in ARC lesion mice and ob/ob mice but not in normal littermates. Unexpectedly, the hypothalamic neuropeptide mRNAs were not altered by single i.c.v. injection. CKD-732 also induced a dose-dependent CTA comparable with LiCl injection, which is a commonly used agent to produce a CTA. In conclusion, CKD-732 causes significant body weight and appetite reduction, possibly by decreasing adiposity directly and inducing central anorexia, which is partly explained by a CTA. These results should be carefully verified to assess the utility of CKD-732 as an anti-obesity drug.